Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

First report of telaprevir-induced pancreatitis.

Ventura C, Urich R, Skinner S, Bina R, Chuang KY, Van Thiel DH, Nadir A.

Dig Dis Sci. 2013 Mar;58(3):887-8. doi: 10.1007/s10620-013-2576-2. Epub 2013 Feb 8. No abstract available.

PMID:
23392743
[PubMed - indexed for MEDLINE]
2.

Telaprevir-induced pityriasis rubra pilaris-like drug eruption.

Stalling SS, Vu JR, English JC.

Arch Dermatol. 2012 Oct;148(10):1215-7. doi: 10.1001/archdermatol.2012.2039. No abstract available.

PMID:
23069976
[PubMed - indexed for MEDLINE]
3.

[Boceprevir and telaprevir: clinical efficacy, safety and drug-drug interactions].

Nikitin AV.

Antibiot Khimioter. 2012;57(9-10):47-9. Review. Russian. No abstract available.

PMID:
23477220
[PubMed - indexed for MEDLINE]
4.

Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C.

[No authors listed]

Med Lett Drugs Ther. 2011 Jul 25;53(1369):57-9. No abstract available.

PMID:
21778964
[PubMed - indexed for MEDLINE]
5.

Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents--a potentially lethal cocktail.

Charlton M.

Hepatology. 2011 Jul;54(1):3-5. doi: 10.1002/hep.24470. No abstract available.

PMID:
21710471
[PubMed - indexed for MEDLINE]
6.

Boceprevir, telaprevir, and rilpivirine hydrochloride.

Hussar DA, Snell CW.

J Am Pharm Assoc (2003). 2012 Jan-Feb;52(1):120-6. doi: 10.1331/JAPhA.2012.12506. No abstract available.

PMID:
22257626
[PubMed - indexed for MEDLINE]
7.

The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.

Pawlotsky JM.

Gastroenterology. 2011 Mar;140(3):746-54. doi: 10.1053/j.gastro.2011.01.028. Epub 2011 Jan 18. No abstract available. Erratum in: Gastroenterology. 2011 Aug;141(2):778.

PMID:
21255572
[PubMed - indexed for MEDLINE]
8.

Telaprevir and anaemia: what we learned from the first three patients.

Sarikaya M, Doğan Z, Ergül B, Filik L.

Scand J Infect Dis. 2013 Jul;45(7):575. doi: 10.3109/00365548.2012.759271. Epub 2013 Jan 9. No abstract available.

PMID:
23301829
[PubMed - indexed for MEDLINE]
9.

Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.

Butt AA, Kanwal F.

Clin Infect Dis. 2012 Jan 1;54(1):96-104. doi: 10.1093/cid/cir774. Epub 2011 Dec 7. Review.

PMID:
22156853
[PubMed - indexed for MEDLINE]
Free Article
10.

[Studies with telaprevir].

[No authors listed]

MMW Fortschr Med. 2011 Jul 21;153(29-31):15. German. No abstract available.

PMID:
21830727
[PubMed - indexed for MEDLINE]
11.

Drugs in development for viral hepatitis: care and caution.

Pockros PJ.

Drugs. 2011 Feb 12;71(3):263-71. doi: 10.2165/11587090-000000000-00000. No abstract available.

PMID:
21319865
[PubMed - indexed for MEDLINE]
12.

Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients.

Gervasoni C, Milazzo L, Pezzani D, Fucile S, Cattaneo D.

AIDS. 2014 Jan 14;28(2):285-7. doi: 10.1097/QAD.0000000000000088. No abstract available.

PMID:
24413314
[PubMed - indexed for MEDLINE]
13.

Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.

Moreno A, Quereda C, Montes M, Pérez-Elías MJ, Casado JL, Rodríguez-Sagrado MA, Mateos ML, Dronda F, Bárcena R, Del Campo S, Moreno S.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):e47-9. doi: 10.1097/QAI.0b013e31826cc275. No abstract available.

PMID:
23095936
[PubMed - indexed for MEDLINE]
14.

Study Results Support Telaprevir-Based Therapy for HCV.

[No authors listed]

AIDS Patient Care STDS. 2010 Nov;24(11):746. No abstract available.

PMID:
21108519
[PubMed - indexed for MEDLINE]
15.

The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.

Gentile I, Carleo MA, Borgia F, Castaldo G, Borgia G.

Expert Opin Investig Drugs. 2010 Jan;19(1):151-9. doi: 10.1517/13543780903501505. Review.

PMID:
20001560
[PubMed - indexed for MEDLINE]
16.

Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.

Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP.

Liver Transpl. 2012 Dec;18(12):1464-70. doi: 10.1002/lt.23542.

PMID:
22941516
[PubMed - indexed for MEDLINE]
Free Article
17.

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S.

Hepatology. 2007 Sep;46(3):640-8.

PMID:
17879366
[PubMed - indexed for MEDLINE]
18.

Protease inhibitors: silver bullets for chronic hepatitis C infection?

Alkhouri N, Zein NN.

Cleve Clin J Med. 2012 Mar;79(3):213-22. doi: 10.3949/ccjm.79a.11082. Review.

PMID:
22383557
[PubMed - indexed for MEDLINE]
19.

Telaprevir: hope on the horizon, getting closer.

Weisberg IS, Jacobson IM.

Clin Liver Dis. 2009 Aug;13(3):441-52. doi: 10.1016/j.cld.2009.05.009. Review.

PMID:
19628160
[PubMed - indexed for MEDLINE]
20.

Is creatinine clearance enough to predict sufficient kidneys for telaprevir?

Sarikaya M, Doğan Z, Ergul B, Filik L.

Scand J Infect Dis. 2014 Jan;46(1):80. doi: 10.3109/00365548.2013.831184. Epub 2013 Sep 19. No abstract available.

PMID:
24047228
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk